Efficacy of Non-invasive Neuromodulation Treatments for Post-covid-19 Sequelae in Patients With Impaired Smell.

Publication date: Aug 06, 2024

The goal of this clinical trial is to demonstrate the effectiveness of non-invasive Neuromodulation as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of COVID-19. It will also estimate the impact of non-invasive Neuromodulation treatment on the functionality and quality of life of patients with COVID-19 sequelae. The main question it aim to answer is: – Is non-invasive Neuromodulation effective as a therapy in neurological, respiratory and musculoskeletal pathologies derived from the consequences of COVID-19? Researchers will compare non-invasive Neuromodulation to a placebo (treatment with the machine turned off). Participants will: * Be evaluated before starting treatment. * Be evaluated 3 weeks after. * Be evaluated at 5 weeks, or 15 sessions or completion of treatment. * Be evaluated 6 weeks after finishing the treatment or 11 weeks after starting treatment.

Concepts Keywords
Covid COVID-19
Olfactory NON INVASIVE NEUROMODULATION
Therapy SMELL
Weeks

Semantics

Type Source Name
disease MESH covid-19
disease MESH Sequelae
disease VO effectiveness
disease IDO quality
disease VO effective
disease IDO history
disease MESH musculoskeletal disease

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *